🇺🇸 FDA
Pipeline program

VQW-765

VP-VQW-765-3201

Phase 3 small_molecule active

Quick answer

VQW-765 for Social Anxiety Disorder (SAD) is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Social Anxiety Disorder (SAD)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials